Improving immunovirotherapies: the intersection of mathematical modelling and experiments
Combined oncolytic virotherapy and immunotherapy (immunovirotherapy) protocols represent a promising treatment strategy for a range of cancers and offer many advantages over conventional anti-cancer therapies. Nevertheless, there are considerable challenges for this therapeutic modality, and clinica...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | ImmunoInformatics |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667119022000039 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846091552101761024 |
|---|---|
| author | Christine E. Engeland Johannes P.W. Heidbuechel Robyn P. Araujo Adrianne L. Jenner |
| author_facet | Christine E. Engeland Johannes P.W. Heidbuechel Robyn P. Araujo Adrianne L. Jenner |
| author_sort | Christine E. Engeland |
| collection | DOAJ |
| description | Combined oncolytic virotherapy and immunotherapy (immunovirotherapy) protocols represent a promising treatment strategy for a range of cancers and offer many advantages over conventional anti-cancer therapies. Nevertheless, there are considerable challenges for this therapeutic modality, and clinical treatment failures remain prevalent. Determining which combination regimens to investigate given the burgeoning number of virotherapy and immunotherapy derivatives remains a tremendous challenge for the field. Fortunately, mathematical modelling is well placed to assist in identifying optimal combination regimens and improving these treatments. However, translation of modelling predictions to actionable changes is severely lacking. Here, two mathematicians and two experimentalists discuss their respective viewpoints concerning the current state of immunovirotherapy, the challenges facing this promising field and how contributions from this modelling and experimental research can be better integrated in the future. By initiating this dialogue, we arrive at the conclusion that the translational process can be improved by first conducting extensive mathematical investigations using relevant data before proceeding to pre-clinical and finally clinical trials. By exploiting mathematical approaches such as virtual clinical trials, we may be able to limit the number of virotherapy and immunotherapy combinations that should be tested clinically. Overall, the current integration of efforts by modellers and experimentalists is insufficient to support major translational advances in this field, and it is only with cross-disciplinary efforts that immunovirotherapy can be a robustly effective cancer treatment. |
| format | Article |
| id | doaj-art-0a413972b96b45f781069e84d224fa3f |
| institution | Kabale University |
| issn | 2667-1190 |
| language | English |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ImmunoInformatics |
| spelling | doaj-art-0a413972b96b45f781069e84d224fa3f2025-01-10T04:38:19ZengElsevierImmunoInformatics2667-11902022-06-016100011Improving immunovirotherapies: the intersection of mathematical modelling and experimentsChristine E. Engeland0Johannes P.W. Heidbuechel1Robyn P. Araujo2Adrianne L. Jenner3National Centre for Tumour Diseases, University Hospital Heidelberg, Department of Medical Oncology and Clinical Cooperation Unit Virotherapy, German Cancer Research Centre, Heidelberg, Germany; Centre for Biomedical Research and Education (ZBAF), School of Medicine, Institute of Virology and Microbiology, Faculty of Health, Witten/Herdecke University, Witten, GermanyNational Centre for Tumour Diseases, University Hospital Heidelberg, Department of Medical Oncology and Clinical Cooperation Unit Virotherapy, German Cancer Research Centre, Heidelberg, GermanySchool of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, AustraliaSchool of Mathematical Sciences, Queensland University of Technology, Brisbane, QLD, Australia; Corresponding author:Combined oncolytic virotherapy and immunotherapy (immunovirotherapy) protocols represent a promising treatment strategy for a range of cancers and offer many advantages over conventional anti-cancer therapies. Nevertheless, there are considerable challenges for this therapeutic modality, and clinical treatment failures remain prevalent. Determining which combination regimens to investigate given the burgeoning number of virotherapy and immunotherapy derivatives remains a tremendous challenge for the field. Fortunately, mathematical modelling is well placed to assist in identifying optimal combination regimens and improving these treatments. However, translation of modelling predictions to actionable changes is severely lacking. Here, two mathematicians and two experimentalists discuss their respective viewpoints concerning the current state of immunovirotherapy, the challenges facing this promising field and how contributions from this modelling and experimental research can be better integrated in the future. By initiating this dialogue, we arrive at the conclusion that the translational process can be improved by first conducting extensive mathematical investigations using relevant data before proceeding to pre-clinical and finally clinical trials. By exploiting mathematical approaches such as virtual clinical trials, we may be able to limit the number of virotherapy and immunotherapy combinations that should be tested clinically. Overall, the current integration of efforts by modellers and experimentalists is insufficient to support major translational advances in this field, and it is only with cross-disciplinary efforts that immunovirotherapy can be a robustly effective cancer treatment.http://www.sciencedirect.com/science/article/pii/S2667119022000039Oncolytic virotherapyImmunotherapyImmunovirotherapyMathematical ModellingAgent-based modellingVirtual clinical trials |
| spellingShingle | Christine E. Engeland Johannes P.W. Heidbuechel Robyn P. Araujo Adrianne L. Jenner Improving immunovirotherapies: the intersection of mathematical modelling and experiments ImmunoInformatics Oncolytic virotherapy Immunotherapy Immunovirotherapy Mathematical Modelling Agent-based modelling Virtual clinical trials |
| title | Improving immunovirotherapies: the intersection of mathematical modelling and experiments |
| title_full | Improving immunovirotherapies: the intersection of mathematical modelling and experiments |
| title_fullStr | Improving immunovirotherapies: the intersection of mathematical modelling and experiments |
| title_full_unstemmed | Improving immunovirotherapies: the intersection of mathematical modelling and experiments |
| title_short | Improving immunovirotherapies: the intersection of mathematical modelling and experiments |
| title_sort | improving immunovirotherapies the intersection of mathematical modelling and experiments |
| topic | Oncolytic virotherapy Immunotherapy Immunovirotherapy Mathematical Modelling Agent-based modelling Virtual clinical trials |
| url | http://www.sciencedirect.com/science/article/pii/S2667119022000039 |
| work_keys_str_mv | AT christineeengeland improvingimmunovirotherapiestheintersectionofmathematicalmodellingandexperiments AT johannespwheidbuechel improvingimmunovirotherapiestheintersectionofmathematicalmodellingandexperiments AT robynparaujo improvingimmunovirotherapiestheintersectionofmathematicalmodellingandexperiments AT adrianneljenner improvingimmunovirotherapiestheintersectionofmathematicalmodellingandexperiments |